116890 | Adenosine Kinase Inhibitor - CAS 214697-26-4 - Calbiochem

116890
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₂₂H₁₉BrN₆O •2HCl 214697-26-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      116890-5MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 5 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable, non-nucleoside pyridopyrimidine compound that acts as a potent, adenosine-competitive, and reversible adenosine kinase (AK) inhibitor (IC50 = 50.7 nM using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK). The inhibitory effect is not species-specific and its pharmacological selectivity is confirmed using a panel of more than 80 other enzymes, ion channels, and receptors, including various adesine receptors. It readily crosses the blood-brain barrier and is shown to be efficacious in in vivo animal models via various administration methods (i.p., p.o., s.c.).
          Catalogue Number116890
          Brand Family Calbiochem®
          Synonyms4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl, ABT-702
          References
          ReferencesDe Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
          Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
          Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
          Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
          Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.
          Product Information
          CAS number214697-26-4
          ATP CompetitiveN
          FormYellow solid
          Hill FormulaC₂₂H₁₉BrN₆O •2HCl
          Chemical formulaC₂₂H₁₉BrN₆O •2HCl
          Hygroscopic Hygroscopic
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetAdenosine Kinase
          Primary Target IC<sub>50</sub>50.7 nM inhibiting adenosine kinase (AK) using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK
          Purity≥90% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          116890

          References

          Reference overview
          De Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
          Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
          Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
          Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
          Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision05-October-2009 JSW
          Synonyms4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl, ABT-702
          DescriptionA cell-permeable, non-nucleoside pyridopyrimidine compound that acts as a potent, adenosine-competitive, and reversible adenosine kinase (AK) inhibitor (IC50 = 50.7 nM using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK). The inhibitory effect is not species-specific and its pharmacological selectivity is confirmed using a panel of more than 80 other enzymes, ion channels, and receptors, including various adesine receptors. It readily crosses the blood-brain barrier and is shown to be efficacious in in vivo animal models via various administration methods (i.p., p.o., s.c.).
          FormYellow solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number214697-26-4
          Chemical formulaC₂₂H₁₉BrN₆O •2HCl
          Structure formulaStructure formula
          Purity≥90% by HPLC
          SolubilityDMSO (20 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesDe Vry, J., et al. 2004. Eur. J. Pharmacol. 491, 137.
          Suzuki, R., et al. 2001. Br. J. Pharmacol. 132, 1615.
          Boyle, D.L., et al. 2001. J. Pharmacol. Exp. Ther. 296, 495.
          Kowaluk, E.A., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1165.
          Jarvis, M.F., et al. 2000. J. Pharmacol. Exp. Ther. 295, 1156.